Skip to main content
Retour
Watch Compare

Xenetic Biosciences, Inc.

Qualité des données : 100%
XBIO
Nasdaq Manufacturing Chemicals
3,06 €
▼ 0,09 € (-2,86%)
Cap. Boursière: 7,22 M
Prix
3,15 €
Cap. Boursière
7,22 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Revenue grew 26,54% annually over 5 years — strong growth
Negative free cash flow of -2,29 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,50%

Croissance

Revenue Growth (5Y)
26,54%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)19,04%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-63,78%
En dessous de la moyenne du secteur (-53,47%)
ROIC-53,28%
Net Margin-90,07%
Op. Margin-95,23%

Sécurité

Debt / Equity
N/A
Current Ratio4,56
Interest Coverage-19,15

Valorisation

PE (TTM)
-2,69
En dessous de la moyenne du secteur (-1,48)
P/B Ratio1,82
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -2,7 -1,5
P/B 1,8 1,6
ROE % -63,8 -53,5
Net Margin % -90,1 -41,5
Rev Growth 5Y % 26,5 1,8
D/E — 0,3

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 -0,34 €
-0,34 € – -0,34 €
 1,90 M 1
FY2026 -3,32 €
-3,32 € – -3,32 €
 2,28 M 1

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -0,52 € -0,22 € +57,7%
Q32025 -0,49 € -0,33 € +32,7%
Q22025 -0,64 € -0,45 € +29,7%
Q12025 -0,72 € -0,59 € +18,1%

All Fundamental Metrics
Growth
Revenue Growth (1Y) 19,04% Revenue Growth (3Y) 8,25%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 26,54% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2,98 M Net Income (TTM) -2,68 M
ROE -63,78% ROA -51,45%
Gross Margin N/A Operating Margin -95,23%
Net Margin -90,07% Free Cash Flow (TTM) -2,29 M
ROIC -53,28% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,56
Interest Coverage -19,15 Asset Turnover 0,57
Working Capital 3,96 M Tangible Book Value 3,96 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,69 Forward P/E N/A
P/B Ratio 1,82 P/S Ratio 2,42
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -31,68%
Market Cap 7,22 M Enterprise Value 7,22 M
Per Share
EPS (Diluted TTM) -1,58 Revenue / Share 1,30
FCF / Share -1,00 OCF / Share -1,00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 85,30%
SBC-Adj. FCF -2,36 M Growth Momentum -7,50

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,98 M 2,50 M 2,54 M 1,71 M 1,16 M
Net Income -2,68 M -3,96 M -4,13 M -6,55 M -5,65 M
EPS (Diluted) -1,58 -2,57 -2,71 -0,46 —
Gross Profit — — — — —
Operating Income -2,83 M -4,20 M -4,52 M -6,72 M -5,75 M
EBITDA — — — — —
R&D Expenses 3,07 M 3,29 M 3,49 M 4,77 M 3,16 M
SG&A Expenses — — — — —
D&A — — — 0,0 0,0
Interest Expense 147 997,0 249 861,0 355 757,0 167 152,0 100 467,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8,36 M 6,90 M 10,61 M 14,72 M 19,82 M
Total Liabilities 968 025,0 894 263,0 809 585,0 1,07 M 1,42 M
Shareholders' Equity 7,40 M 6,01 M 9,80 M 13,65 M 18,39 M
Total Debt — — — — —
Cash & Equivalents — — — — —
Current Assets 8,05 M 6,59 M 9,59 M 13,65 M 18,72 M
Current Liabilities 968 025,0 894 263,0 809 585,0 1,07 M 1,42 M